First-day pop for Y-mAbs after upsized $110M IPO

Cancer company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) gained $8 (50%) to $24 on Sept. 21 after raising $110.4 million through the sale of 6.9 million shares at $16 in an IPO. BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG are the offering's underwriters.

The offering price valued Y-mAbs at $533 million. Y-mAbs hoped to sell 5.3 million shares at $14-$16...